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Summary
Background—Human eNOS (NOS3) polymorphisms that lower its expression are associated 
with advanced diabetic nephropathy (DN), and the lack of eNOS accelerates DN in diabetic mice. 
Diabetes is associated with fibrin deposition. Lack of nitric oxide and fatty acids stimulate the NF-
kB pathway, which increases tissue factor (TF).
Objectives—To test the hypothesis that TF contributes to the severity of DN in the diabetic 
eNOS-/- mice fed a high fat (HF) diet.
Methods—We made eNOS-/- and wild type mice diabetic with streptozotocin. Half of them were 
placed on a high fat (HF) diet.
Results—Blood glucose levels were not affected by either the diet or eNOS genotype. Lack of 
eNOS in the diabetic mice increased urinary albumin excretion, glomerulosclerosis, interstitial 
fibrosis, and glomerular basement membrane thickness. HF by itself did not affect DN in the wild 
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type mice, but significantly enhanced DN in eNOS-/- mice. More than half of diabetic eNOS-/- 
mice on HF died prematurely with signs of thrombotic complications. Diabetic kidneys contained 
fibrin and TF, and their levels were increased by the lack of eNOS and by HF in an additive 
fashion. The HF diet increased the kidney expression of inflammatory genes. The increase in TF 
preceded DN, and administration of an anti-mouse TF antibody to diabetic mice reduced the 
expression of inflammatory genes.
Conclusion—Together, these data indicate a causal link between TF and the exacerbation of DN 
in eNOS-/- mice. The condition is significantly worsened by enhanced inflammatory responses to 
a HF diet via TF.
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Introduction
Clinical studies have shown that 30-40% of diabetic patients develop DN [1], which is the 
most frequent cause of chronic kidney disease and is also a risk factor for stroke and heart 
attack [2]. The development and severity of DN vary greatly from one patient to another, 
with familial clustering suggesting that genetic factors play an important role [3]. Current 
knowledge of the susceptibility genes for DN and of their interactions with environmental 
factors is, however, very limited.
The mouse is a relatively poor model for DN, exhibiting only a limited extent of the 
pathology. Recently, however, multiple laboratories have demonstrated that diabetic mice 
that lack eNOS develop human like nephropathy [4-6]. These observations, together with the 
well-documented associations between advanced nephropathy in patients with either type I 
or type II diabetes and NOS3 gene polymorphisms that lead to reduced expression of eNOS 
[7, 8], underscore the facilitating role of endothelial dysfunction in the pathogenesis of DN. 
In addition to a blunted acetylcholine-induced vasodilatation, mice lacking eNOS have high 
blood pressure (BP), insulin resistance, and glucose intolerance without obvious kidney 
abnormalities [9, 10]. Nitric oxide (NO) generally acts as an antioxidant and exerts anti-
thrombotic effects [11]. Under some circumstances, possibly including diabetes, however, 
eNOS might actually increase oxidative stress [12]. Thus, the precise molecular pathways 
underlying the accelerated DN associated with eNOS deficiency warrant investigation.
In the present study, we tested the hypothesis that hypercoagulability is a key factor 
determining the severity of nephropathy in diabetic eNOS-/- mice. We focused our attention 
on tissue factor (TF), which initiates the main coagulation cascade. TF expression is induced 
by the activation of the NF-kB pathway [13, 14], which is inhibited by NO [15] and 
stimulated by fatty acids [16]. Accordingly, we investigated the effects on DN of the lack of 
eNOS and a high fat (HF) diet that is adjusted to diets consumed in Western societies. We 
here show that these two factors additively increase TF expression in diabetic kidneys, and 
that, when combined, they dramatically exacerbate DN. Administration of anti-TF antibody 
corrected the increase in the expression of inflammatory genes in the kidney of diabetic mice 
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by lack of eNOS and HF, indicating that TF contributes to the severity of DN in diabetic 
eNOS-/- mice fed HF.
Methods
Animals
Animal experiments were conducted in accordance with the guideline of IACUC at UNC at 
Chapel Hill. Male eNOS -/- mice (Nos3tm1Unc [9]) and their WT littermates, backcrossed at 
least 10 times to C57BL/6J, were used in this study. Diabetes was induced in 4∼6-month-old 
male mice by intraperitoneal injection of streptozotocin (STZ, 40 mg/kg, Sigma) for 5 
consecutive days after 4-hour fasting as previously described [17]. Animals were maintained 
without insulin treatment for 6 months. Mice having plasma glucose concentration equal to 
or greater than 300 mg/dl throughout the study after STZ injection were defined as diabetic 
and included in the study. Both diabetic and non-diabetic control mice (injected with buffer 
only) were randomly divided and fed either normal chow (NC, 14% calories from fat) or a 
HF diet (42% calories from fat, TD88137, Harlan Teklad). At 3 and 6 months after inducing 
diabetes, the individual mice were placed in metabolic cages. Body weight, food and water 
intake, and urine volume were measured at 24 and 48 hrs. Blood samples were collected at 
the end of the metabolic cage study. Mice were then sacrificed for further analysis. For 
testing short-term effect of diabetes, 3∼4 month-old male eNOS-/- and WT mice were 
injected with STZ or buffer only, fed with NC or HF, and analyzed 5 weeks later. To test 
whether TF exacerbates DN a single dose at 100 μg/mouse of an anti-mouse TF neutralizing 
antibody AF3178 (R&D) was administered intraperitoneally 5 weeks after STZ injection. 
Mice were sacrificed 4 days later for further analysis. [Our data show that 100 μg/mouse of 
anti-TF neutralizing antibody inhibits 70 % of the TF activity in the kidney without bleeding 
complication.]
BP and glomerular filtration rate (GFR) measurements
BP was measured by the computerized tail-cuff method for 6 days [18]. All mice were 
trained 10 cycles of measurements on the BP apparatus before 30 measurements were made 
each day. GFR was estimated by measuring the plasma and urinary creatinine using LC-
MS/MS [19].
Biochemical measurements
Urinary albumin was determined using Albuwell-M kits (Exocell Inc.). Urinary 8-
hydroxy-2′-deoxyguanosine (8-OHdG) was measured with an ELISA kit (The Japan 
Institute for The Control of Aging). Plasma CML was measured with an ELISA kit (CycLex 
Co.). Plasma thrombin-antithrombin (TAT) complexes were measured with the AssayMax 
TAT complexes ELISA kit (Assaypro Co.). For PT and aPTT determination, blood was 
collected in glass tubes containing 3.8% trisodium citrate (1 vol citrate plus 9 vol blood), 
and PT and aPTT were measured using a thromboplastin reagent and aPTT reagent 
(Biomerieux Inc.), respectively [20, 21]. Kidney cortex (10 mg) was homogenized in 1ml 
PBS for measuring CML content [22] and TF-dependent procoagulant activity [23].
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The kidney tissue was snap frozen in liquid nitrogen, and the RNA was extracted using 
Trizol (Life Technologies). Gene expression was quantified with TaqMan real-time 
quantitative RT-PCR (Applied Biosystems) with β-actin as a reference gene [18]. The 
primers and probes used are listed in the Online Appendix Table 1.
Kidney morphometry and immunohistochemistry
Cross paraffin sections of kidneys containing papilla (4 μm thick) were stained with Periodic 
Acid-Schiff (PAS) and with Masson's trichrome, and scanned using a NIKON Microphot-
FCA 216567. Glomerulosclerosis was defined as synechiae formation with global 
obliteration of the capillary loops [24]. The number of sclerosed glomeruli was expressed as 
a percentage of the total number of glomeruli. The mesangial matrix score was defined as 
the ratio of the mesangial matrix area divided by the glomerular tuft area [24, 25], and was 
measured using the Image J program. All of the glomeruli (90 to 110) in each section were 
measured. Tubulointerstitial fibrosis was scored by using 10∼15 fields of the cortex at a 
magnification of × 4 with a scale of 0 to 4: 0, no fibrosis; 1, <25%; 2, 25-50%; 3, 50-75%; 4, 
>75% of the field with interstitial fibrosis [25]. For GBM thickness, transmission electron 
micrographs at a magnification of ×5,000 were printed, and the thickness of the GBM of 
capillary loops was measured manually. Rabbit anti-human fibrinogen polyclonal antibody 
(1:2000; Dako A0080) was used for immunohistochemical detection of fibrin. This antibody 
recognizes mouse fibrin but not mouse fibrinogen [26, 27]. Monoclonal rat anti-mouse TF 
antibody (1H1) was kindly provided by Dr. Daniel Kirchhofer (Genetech) [28]. The antigen 
was retrieved with a citrate buffer method [29]. For double staining of TF and MOMA-2, a 
monoclonal rat antibody against mouse MOMA-2 (1:25, AbD Serotec) preincubated with 
goat anti-rat immunoglobulins labeled with FITC (1:50, Jackson ImmunoResearch), 
followed by 1H1 preincubated with goat anti-rat immunoglobulins labeled with Rhodamine 
Red-X (1:50, Jackson ImmunoResearch) were used. Sections were analyzed using confocal 
laser scanning microscopy LSM5PASCAL (Carl Zeiss).
Mouse mesangial cell culture
Mouse mesangial cells (ATCC, CRL-1927) were cultured in DMEM with high glucose 
(4g/L) containing 10% (vol/vol) FBS, 10 mg/ml streptomycin, and 100 U/ml penicillin at 
37°C in 5% CO2-air. Two days after confluence, FBS was replaced by 0.5% mouse serum 
for 48 hrs. Cells were then treated with mouse factor VIIa (50 nM, generous gift from Dr. 
Lars Petersen, Novo Nordisk, Bagsvaerd, Denmark) for 6 hrs, and harvested and SNAP 
frozen in liquid nitrogen for further analysis.
Statistical analysis
Data were expressed as mean ± SEM. Multifactorial ANOVA with the program JMP 8.0 
(SAS Institute Inc.) was used to compare the effects of diabetes, eNOS genotypes, diets, and 
of their combinations. Tukey-Kramer HSD test was used for posthoc comparisons between 
each group.
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Survival of diabetic mice
The eNOS-/- mice and their WT littermates were made diabetic by repeated injections of 
low-dose streptozotocin (STZ) at 4-6 months of age. Control non-diabetic groups were 
treated with buffer only. Both the diabetic and non-diabetic mice were randomly divided into 
two groups and fed either normal chow (NC) or a high fat diet (HF) for 6 months. The 
general characteristics of the diabetic mice are presented in Online Appendix Table 2. 
Because there were no remarkable differences in the DN parameters measured among the 
four non-diabetic groups (WT NC, WT HF, eNOS-/- NC, eNOS-/- HF), we focus only on 
the data from the four groups of diabetic mice in the following analysis, unless otherwise 
noted.
The absence of eNOS increased tail-cuff BP by approximately 15∼20 mmHg (p<0.0001), 
but did not affect the plasma glucose levels. BP was not affected by diabetes or by the diet, 
and did not significantly change in the 6 month study in any group of mice. eNOS deficiency 
caused premature death in diabetic mice, and 4 out of 11 (∼30%) of the diabetic eNOS-/- 
mice fed NC died by 6 months after the induction of diabetes (Fig. 1A). Although HF did 
not affect the survival of diabetic WT mice, 8 out of 14 (∼60 %) of the diabetic eNOS-/- 
mice fed HF died (Fig. 1A). In some cases at necropsy there was evidence of clots in the 
mesenteric arteries and necrosis of the small intestine, suggesting ischemic events. Some 
exhibited massive bleeding in the abdominal cavity or in the lung (Online Appendix Fig. 1) 
without clear evidence of dissection of the aorta, stroke, myocardial infarction, or apparent 
intravascular coagulations in other tissues, including the liver, heart and brain (not shown). 
We conclude that lack of eNOS causes premature death of diabetic mice involving 
hypercoagulability, and that HF accelerates premature death only when the animals are 
deficient of eNOS.
Diabetic nephropathy (DN)—When the animals were fed NC, eNOS-/- mice that were 
diabetic for 6 months had increased urinary albumin excretion without significant decrease 
in creatinine clearance compared to diabetic mice with WT eNOS (Figs. 1B, C). Diabetic 
eNOS-/- mice fed NC had a severe glomerulosclerosis that was not seen in any of the 
diabetic WT mice (Figs. 2B, 2E). They also had severely exacerbated tubulointerstitial 
fibrosis and thickening of glomerular basement membrane (GBM) (Figs. 2G, 2H).
The high fat diet did not alter kidney function in diabetic WT mice, although in eNOS-/- 
mice albuminuria and GFR showed a trend of worsening by HF (Figs. 1B,1 C). HF did not 
significantly increase the mesangial score and the tubulointerstitial fibrosis score compared 
to NC regardless of eNOS genotype (Figs. 2F, 2G), but more than doubled the number of 
glomeruli with sclerosis in the diabetic eNOS-/- mice (Figs. 2D-2E, online Appendix Fig. 2). 
HF also significantly increased GBM thickness in the diabetic eNOS-/- mice (Fig. 2H). In 
transmission electron micrographs, endothelial cells, fenestrae, and podocytes appeared 
normal in the kidneys of all mice, while thickening of GBM in eNOS-/- diabetic mice on NC 
and HF was evident (online Appendix Fig. 3). We conclude that the lack of eNOS 
accelerates both the functional and morphological changes that accompany DN, but that HF 
accelerates it only when the animals are deficient of eNOS.
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Kidney TF and inflammation—To investigate if there was an activation of coagulation in 
DN, fibrin deposition in the kidneys was examined. There was no apparent fibrin deposition 
in the kidneys of non-diabetic mice regardless of the diet or eNOS genotype (not shown). 
However, the glomeruli of all of the diabetic mice were positive for fibrin (Fig. 3A). 
Diabetic eNOS-/- mice fed NC showed increased fibrin deposits in the glomeruli compared 
to WT control mice (Fig. 3A top panels). HF also increased fibrin deposition in the 
glomeruli, and the diabetic eNOS-/- mice on HF had the most abundant fibrin deposits in 
their glomeruli among all groups (Fig. 3A bottom panels).
Because TF initiates blood coagulation, we measured TF expression in the kidney and the 
TF-dependent clotting time of kidney homogenates as an index of kidney TF activity [23]. 
Both eNOS deficiency and HF significantly and additively increased renal TF mRNA levels 
and activities (Figs. 3B, 3C). Again, diabetic eNOS-/- mice on HF had the highest TF 
expression and activities. The glomeruli of non-diabetic mice were negative for 
immunoreactive TF (not shown). However, glomeruli of all diabetic mice were positive for 
TF immunoreactivity, and diabetic eNOS-/- mice fed HF showed the most prominent TF 
immunoreactivity in their glomerular mesangial area (Fig. 3D). All cells in the kidney that 
were strongly positive for TF were monocytes/macrophages, while no MOMA-2 positive 
cells were negative for TF (Fig. 3D). No apparent TF immunoreactivity was detected outside 
glomeruli. We conclude that both lack of eNOS and HF independently and additively 
increase kidney TF, HF increases kidney TF regardless of the presence or absence of eNOS, 
and that TF was co-localized with monocytes/macrophages in the glomeruli.
TF, a lack of eNOS and diabetes are all known to enhance inflammation [30-32]. Thus, we 
next quantified the gene expression in the kidney of MCP-1, ICAM-1, VCAM1, IL-1β, 
TNFα, and IL-6. Diabetes markedly increased the expression of all of these genes (Online 
Appendix Table 3). In non-diabetic mice HF significantly increased the expression of 
ICAM-1 and VCAM-1 by 50% to 200%, while the lack of eNOS itself had no significant 
effect. However, when mice were diabetic, the lack of eNOS significantly increased the renal 
expression of ICAM-1 and VCAM-1. Lack of eNOS and HF synergistically increased the 
expression of IL-1β and IL-6 in diabetic mice. Furthermore, linear regression analyses at the 
individual animal level showed that the levels of urinary albumin excretion, GBM thickness, 
and tubulointerstitial fibrosis were all strongly correlated with TF levels (Online Appendix 
Fig. 4). These data demonstrate that diabetes and lack of eNOS interactively increase the 
expression of cell adhesion molecules in the kidney. The data also strongly suggest that a HF 
diet contributes to the exacerbation of DN in diabetic eNOS-/- mice through the stimulation 
of inflammatory processes.
In order to test whether the coagulation abnormalities are systemic or are restricted to the 
kidney, we measured the prothrombin time, PT, and activated partial thromboplastin time, 
aPTT. The lack of eNOS and HF themselves had no effect on these two parameters (Table 
1). However the diabetic eNOS-/- mice on HF had significantly shorter aPTT than other 
groups of diabetic mice, although reduction of their PT did not reach significance. A lack of 
eNOS and HF in diabetic mice tended to increase circulating thrombin-anti-thrombin (TAT) 
complexes, a sensitive marker of thrombin formation. When combined, the lack of eNOS 
and HF caused an increase in circulating TAT complexes. These results demonstrate that the 
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absence of eNOS increases systemic hypercoagulability in diabetic mice, and the condition 
is significantly exacerbated further by HF.
Role of TF in the exacerbation of DN in mice lacking eNOS—We now know that 
TF is associated with DN, but whether an increase in TF is a cause or the result of DN is not 
clear. If TF contributes to DN, an increase in TF precedes the development of DN. If TF is a 
result of DN, TF does not increase until DN develops. To test this, we examined eNOS-/- 
and WT mice 5 weeks after diabetes were induced by STZ. At this early time points, urinary 
albumin excretion did not significantly increase (Fig. 4A). There was no difference in 
urinary albumin excretion and GFR between diabetic and non-diabetic mice in both WT and 
eNOS-/- mice even when the animals were 3 months of diabetes except eNOS-/- diabetic 
mice on HF had higher urinary albumin excretion than non-diabetic eNOS-/- mice on HF 
(online Appendix Figure 5). Kidneys from both eNOS-/- and WT mice that were diabetic for 
5 weeks did not show apparent histological changes suggestive of DN (Fig. 4B). However, 
the renal expression of TF in the diabetic mice was already significantly higher than that of 
non-diabetic mice, reaching to the similar levels as those at 6 months of diabetes (online 
Appendix Fig. 6). Diabetic eNOS-/- mice had higher TF expression than diabetic WT mice 
(Fig. 4C). Similar to kidneys in mice that were diabetic for 6 months, TF is expressed in 
macrophages in glomeruli at this early stage of diabetes (Fig. 4D). All cells in the kidney 
that were strongly positive for TF were monocytes/macrophages; no MOMA-2 positive cells 
were negative for TF. No TF immunoreactivity was detected outside glomeruli.
Although TF is mainly expressed in macrophages residing in mesangial area but not in 
mesangial cells in vivo, it could still activate coagulation cascade in mesangial area using 
coagulation factors from the circulation, and facilitate inflammatory and fibrogenic gene 
expression. Consistent with this possibility, treatment of mouse mesangial cells CRL-1927 
with mouse Factor VIIa, in culture significantly increased the expression of MCP-1, but not 
TGFβ1 or type IV collagen in 6 hrs (Online Appendix Fig. 7).
We next tested whether blocking TF can abrogate the exacerbation of DN in vivo. Five 
weeks after induction of diabetes and fed either NC or HF, we administered to half of the 
animals a polyclonal anti-mouse TF neutralizing antibody AF3178 (100 μg/mouse i.p. once), 
and to the other half normal goat IgG. Four days later animals were sacrificed and kidneys 
analyzed for TF activities and inflammatory and fibrogenic gene expression. The anti-TF 
antibody decreased TF activity in the kidneys by 70%, and significantly suppressed the renal 
expression of several inflammatory and fibrogenic genes in diabetic WT mice fed either NC 
or HF (Fig. 5). Remarkably the anti-TF antibody reduced the induction of inflammatory and 
fibrogenic genes in the kidneys from diabetic eNOS-/-mice fed NC (Fig. 5). Unfortunately, 
we do not have data from the eNOS-/- mice fed HF because most of them died before 
administering anti-TF neutralizing antibody. Taken together, these data indicate that TF 
increases earlier than the development of DN, enhances inflammation in mesangial area, and 
plays a critical role in the pathogenesis of DN induced by a lack of eNOS and HF diet.
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Influence of BP and of oxidative stress on DN in mice lacking eNOS
High BP is a factor known to accelerate DN [30]. The BP values of the eNOS-/- mice were 
higher than the WT mice by approximately 15∼20 mmHg (Online Appendix Table 2). 
However, linear regression analysis showed that urinary albumin excretion of the individual 
animals is only very weakly correlated with BP (p=0.06, R2=0.16), and accounted for less 
than 20% of the variance in the parameters of DN, and thus renal injury in diabetic eNOS-/- 
mice is largely independent of BP. While the lack of eNOS may lead to ischemia from 
intense vasoconstriction in the kidney and renal injury, expression of the HIF-1α gene was 
similar among all groups of mice (Online Appendix Fig. 8), suggesting that ischemia is not a 
likely cause of renal injury in our mice.
Oxidative stress also plays an important role in DN [31], and diabetes significantly increases 
the markers of oxidative stress such as plasma and renal Nε-carboxymethyllysine (CML) 
and urinary 8-hydroxy-2′-deoxyguanosine (8OHdG) (not shown). Neither the lack of eNOS 
nor a HF diet increased the levels of these markers in diabetic mice by itself (Online 
Appendix Fig. 9). Surprisingly, however, lack of eNOS and HF synergistically decreased 
plasma CML and urinary 8OHdG. These data indicate that the exacerbation of DN caused 
by lack of eNOS and HF is not due to an increase in oxidative stress.
Discussion
We have demonstrated that the lack of eNOS causes premature death of diabetic mice and 
exacerbates DN with signs of thrombotic complications. A high fat (HF) diet by itself did 
not cause premature death or exacerbation of DN of diabetic WT mice, but in the absence of 
eNOS HF further decreased survival rate and accelerated DN. Diabetic eNOS-/- mice fed a 
HF diet show more severe diabetic glomerulosclerosis than that reported to date in any 
experimental animal model. When the coagulation pathway is highly activated, large 
amounts of coagulation factors are produced and consumed, which can lead to clotting, 
necrosis and bleeding. Although we do not know the values of platelets and coagulability in 
the animals that died with bleeding, consumption coagulopathy is a likely explanation of the 
hemorrhagic events we observed in some of the eNOS-/- diabetic mice.
The role of NO in thrombus formation is controversial [11, 32]. Kidneys from our non-
diabetic mice, regardless of their eNOS genotype and diet, did not exhibit fibrin deposition, 
indicating that the absence of eNOS alone is not sufficient to induce the deposition of fibrin. 
In contrast, all diabetic mice showed fibrin deposition in the kidneys, and both the lack of 
eNOS and HF markedly increased renal fibrin deposition only when the animals were 
diabetic (Fig. 3A). Fibrin deposition in the glomeruli has also been reported in IgA 
nephropathy and mesangioproliferative glomerulonephritis [33, 34]. In these conditions, 
coagulation in the glomeruli leads to extracellular matrix accumulation [33]. The mesangial 
expansion and glomerulosclerosis in the kidneys of our diabetic animals may also be the 
sequelae of fibrin deposition in the glomeruli.
TF triggers coagulation cascade. NO inhibits [15] and HF stimulates the NF-kB pathway 
[35], one of the most important regulators of TF expression [13, 14]. Accordingly, we 
investigated the effects of eNOS and HF on TF. The results obtained here show that lack of 
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eNOS and HF independently and additively increased TF expression in monocytes/
macrophages of the kidney glomeruli (Figs. 3B, 3C, 3D). These results are consistent with 
previous observations that TF expression is increased in monocytes from diabetic patients 
[36, 37].
Lack of eNOS increased TF expression and activity, and had significant effects on 
parameters of DN. In contrast, HF increased TF expression and activity in diabetic WT mice 
to a similar degree as lack of eNOS did, but it did not significantly exacerbate DN. However, 
HF had significant effects in glomerulosclerosis and GBM thickness in diabetic eNOS-/- 
kidneys. It is likely that eNOS-derived NO protects kidneys from TF-induced damage, and 
that lack of eNOS discloses the TF-induced renal damage. HF causes numerous 
abnormalities including inflammation, obesity, hypertension, and insulin resistance. 
However, anti-TF antibody reduced the increase in expression of inflammatory and 
fibrogenic genes in diabetic mice fed HF, suggesting the pivotal role of TF in HF-induced 
inflammation. This supports our conclusion that increased TF expression, which precedes 
overt DN, plays an important role in the pathogenesis of DN in diabetic eNOS-/- mice.
Increased TF expression in the kidney activates the coagulation cascade, leading to the 
production of factor VIIa, factor Xa and thrombin. These proteases can activate protease-
activated receptors, which may enhance DN [38]. TF can also mediate inflammation [39]. 
Indeed lack of eNOS and HF synergistically increased inflammatory gene expression in the 
kidneys of diabetic mice (on-line Appendix Table 3). The expression levels of these genes 
were found to be associated with the variations in DN parameters observed in the present 
study. Inflammation, in turn, promotes coagulation by further recruiting monocytes/
macrophages, and by increasing TF expression, and exacerbates DN.
Although increased TF is associated with the severity of DN, it was not clear whether an 
increase in TF is a result or cause of DN. Our data from mice 5 weeks after induction of 
diabetes show that an increase in TF and inflammatory and fibrogenic gene expression 
precedes the development of DN. Moreover, an anti-TF neutralizing antibody reduced the 
increase in the expression of inflammatory and fibrogenic genes (Fig. 5). These data are 
consistent with the fact that TF can mediate inflammation [39], and strongly suggest that the 
increase in TF plays a causative role in the exacerbation of DN. TF expression in 
macrophages of the kidney glomeruli at both 5 weeks and 6 months of diabetes (Figs. 3D, 
4D) is consistent with previous observations that TF expression is increased in monocytes 
from diabetic patients [36, 37]. Although macrophages likely infiltrate in mesangial area to 
clean up the aftermath of glomerular injury, macrophage TF likely causes further renal 
injury. Although immunoreactive TF was not detected in mesangial cells in vivo, mesangial 
cells are suggested to be responsible for mesangial expansion and glomerulosclerosis in DN 
[40, 41]. When macrophages in mesangial area express TF and activate coagulation cascade, 
Factor VIIa, Factor Xa, and thrombin are produced, which could increase the expression of 
inflammatory genes such as MCP-1 in mesangial cells in vitro possibly through binding to 
protease activated receptors. Our data showing that FVIIa increases MCP-1 expression in 
mesangial cells in vitro are consistent with this hypothesis (online Appendix Fig. 7). These 
results suggest that the increase in TF likely causes the exacerbation of DN. Although they 
do not exclude the possibility that hypercoagulability is induced secondary to inflammation, 
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hypercoagulability and inflammation together likely make a vicious circle in exacerbating 
DN.
DN in eNOS-/- mice includes marked tubulointerstitial fibrosis, which requires some 
comments. Although all the eNOS-/- diabetic mice reported to date including this study 
show glomerulosclerosis [4-6], the development of tubulointerstitial fibrosis in these mice 
has been controversial [5, 42, 43]. For example, Kosugi et al. used high dose STZ to make 
the eNOS-/- mice diabetic, and observed robust tubulointerstitial damage [42]. In contrast, 
Kanetsuna et al. used low dose STZ and reported that diabetic eNOS-/- mice did not develop 
significant tubulointerstitial damage [6]. We used a similar low dose STZ, and observed that 
the lack of eNOS was sufficient to cause tubulointerstitial fibrosis. All of these three studies 
used eNOS-/- mice on C57BL/6J genetic background. Although tubulointerstitial damage of 
high dose STZ mice was reversed by administration of insulin, suggesting this phenotype is 
due to diabetes rather than to toxicity of STZ [42], high dose STZ eNOS-/- mice have about 
30 mmHg higher tail-cuff BP than ours. This malignant hypertension could be triggered by 
STZ-induced tissue damage [43], and contribute to the development of tubulointerstitial 
fibrosis. Our observation that a HF diet enhances DN dramatically only in diabetic eNOS-/- 
kidneys suggests that other environmental factors that increase inflammatory burdens cannot 
be ignored.”
High BP is known to exacerbate DN [30], and it is likely that high BP plays some role in 
exacerbating DN of mice lacking eNOS as previously suggested [42]. However, as judged 
by linear regression analysis, the contribution of BP to DN in diabetic eNOS-/- mice is small 
in our experiment. In addition, although oxidative stress greatly contributes to the 
development of DN [44], our diabetic eNOS-/- mice showed reduced oxidative stress 
compared to the diabetic mice with wild type eNOS. This finding is consistent with the 
concept of eNOS uncoupling in diabetes, where eNOS generates superoxide rather than NO 
[45], and indicate that the protective role of eNOS in DN is not mediated by a reduction of 
oxidative stress caused by diabetes, but through prevention of monocytes recruitment to the 
mesangial area.
In conclusion, our data demonstrate that lack of eNOS and HF additively increase kidney TF 
expression in the diabetic kidneys, which likely causes acceleration of DN. HF stimulates 
inflammatory response in diabetic eNOS-/- mice without any further increase in oxidative 
stress compared to WT diabetic mice. The increase in BP caused by lack of eNOS appears to 
play a minimal role. These findings suggest that the major determinant of DN in eNOS-/- 
diabetic mice is an upregulation of coagulation and inflammation via increased TF 
expression. Taken together, it is suggested that hypercoagulability is more important in the 
pathogenesis of DN than has previously been recognized, and that kidney TF expression is 
an excellent marker of the severity of DN.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Survival rates and renal function after 6 months of diabetes
A, Survival rates of wild type (WT) and eNOS-/- diabetic mice fed normal chow (NC) or a 
high fat (HF) diet. B, daily urinary albumin excretion of diabetic mice. C, creatinine 
clearance of diabetic mice. Data are expressed as mean ± SEM, n≥6. The creatinine 
clearance of non-diabetic age-matched mice was: 275 ± 80 μl/min (WT on NC), 249 ± 77 
(eNOS-/- on NC), 340 ± 65 (WT on HF), 322 ± 72 (eNOS-/- on HF).
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Figure 2. Renal morphology of the diabetic mice
A, wild type diabetic mouse fed normal chow; B, eNOS-/- diabetic mouse fed normal chow; 
C, wild type diabetic mouse fed a high fat diet; D, eNOS-/- diabetic mouse fed a high fat 
diet; E-H, quantification of histological changes. A-D, Masson Trichrome staining, original 
magnification × 40. The arrow heads and a yellow arrow show glomerulosclerosis and 
tubulointerstitial fibrosis, respectively. Higher magnification of glomeruli and transmission 
electron micrographs of glomerular capillary walls are shown in online Appendix Figs. 2 
and 3.
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Figure 3. Fibrin deposit and Tissue factor (TF) expression in the kidneys of mice diabetic for 6 
months
A. fibrin deposit in the kidneys of diabetic mice. Diabetic eNOS-/- mice on a high fat diet 
had prominent fibrin deposits in glomeruli. Original magnification ×100. B. kidney TF 
mRNA levels expressed in fold change relative to WT diabetic mice on NC. TF expression 
of 8 groups of mice including 4 non-diabetic groups can be found in online Appendix Fig. 6. 
p<0.001 for eNOS genotype effect, and diet effect. There was no interaction between eNOS 
genotype and diet. C, kidney cortex TF activities of diabetic mice. D, immunostaining 
against TF and monocytes/macrophages (MOMA-2) in a diabetic eNOS-/- mouse on a high 
fat diet. The left lower panel is a differential interference contrast image of the glomerulus.
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Figure 4. An increase in kidney tissue factor expression precedes the development of DN
Mice were diabetic for 5 weeks and fed normal chow. Urinary albumin excretion (A) and 
kidney histology (B. PAS staining, original magnification ×200) did not differ among the 4 
groups. In contrast, TF mRNA expression (fold WT control) in the kidneys (C) was 
significantly increased by diabetes and by lack of eNOS. D, Immunostaining of glomeruli 
against TF and monocytes/macrophages (MOMA-2) in a diabetic eNOS-/- mouse. Data are 
expressed as mean ± SEM, n≥5 each group.
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Figure 5. Attenuation of the expression of inflammatory and fibrogenic genes by an anti-mouse 
TF antibody AF3178
All mice were made diabetic with STZ. A single dose of AF3178 (100μg) was administered 
i.p. 5 weeks after STZ injection, and mice were sacrificed for analysis 4 days later. C: 
control, AF: AF3178, NC: normal chow, HF: high fat diet. Data are mean ± SEM relative to 
the mean of diabetic WT mice fed NC, n≥5.
Li et al. Page 18

































































































































































































































































































































































































J Thromb Haemost. Author manuscript; available in PMC 2017 December 27.
